| Replacement, reduction, and refinement of animal experiments in anticancer drug development: the contribution of 3D in vitro cancer models in the drug efficacy assessment EM Tosca, D Ronchi, D Facciolo, P Magni Biomedicines 11 (4), 1058, 2023 | 59 | 2023 |
| Staggered herringbone microfluid device for the manufacturing of chitosan/TPP nanoparticles: Systematic optimization and preliminary biological evaluation E Chiesa, A Greco, F Riva, EM Tosca, R Dorati, S Pisani, T Modena, ... International journal of molecular sciences 20 (24), 6212, 2019 | 35 | 2019 |
| Application of artificial neural networks to predict the intrinsic solubility of drug-like molecules EM Tosca, R Bartolucci, P Magni Pharmaceutics 13 (7), 1101, 2021 | 29 | 2021 |
| Modeling tumor growth inhibition and toxicity outcome after administration of anticancer agents in xenograft mice: a dynamic energy budget (DEB) approach N Terranova, EM Tosca, E Borella, E Pesenti, M Rocchetti, P Magni Journal of theoretical biology 450, 1-14, 2018 | 15 | 2018 |
| A tumor-in-host DEB-based approach for modeling cachexia and bevacizumab resistance EM Tosca, M Rocchetti, E Pesenti, P Magni Cancer Research 80 (4), 820-831, 2020 | 14 | 2020 |
| Modeling approaches for reducing safety-related attrition in drug discovery and development: a review on myelotoxicity, immunotoxicity, cardiovascular toxicity, and liver toxicity EM Tosca, R Bartolucci, P Magni, I Poggesi Expert Opinion on Drug Discovery 16 (11), 1365-1390, 2021 | 13 | 2021 |
| In vitro–in vivo correlation (Ivivc) population modeling for the in silico bioequivalence of a long-acting release formulation of progesterone EM Tosca, M Rocchetti, E Pérez, C Nieto, P Bettica, J Moscoso del Prado, ... Pharmaceutics 13 (2), 255, 2021 | 13 | 2021 |
| A population dynamic energy budget-based tumor growth inhibition model for etoposide effects on Wistar rats EM Tosca, MC Pigatto, T Dalla Costa, P Magni Pharmaceutical research 36, 1-13, 2019 | 12 | 2019 |
| Model‐based prediction of effective target exposure for MEN1611 in combination with trastuzumab in HER2‐positive advanced or metastatic breast cancer patients EM Tosca, E Borella, C Piana, S Bouchene, G Merlino, A Fiascarelli, ... CPT: Pharmacometrics & Systems Pharmacology 12 (11), 1626-1639, 2023 | 9 | 2023 |
| A translational model-based approach to inform the choice of the dose in phase 1 oncology trials: the case study of erdafitinib EM Tosca, N Terranova, K Stuyckens, AG Dosne, T Perera, J Vialard, ... Cancer Chemotherapy and Pharmacology 89 (1), 117-128, 2022 | 9 | 2022 |
| Modeling restoration of gefitinib efficacy by co‐administration of MET inhibitors in an EGFR inhibitor‐resistant NSCLC xenograft model: a tumor‐in‐host DEB‐based approach EM Tosca, G Gauderat, S Fouliard, M Burbridge, M Chenel, P Magni CPT: Pharmacometrics & Systems Pharmacology 10 (11), 1396-1411, 2021 | 9 | 2021 |
| A Dynamic Energy Budget (DEB) based modeling framework to describe tumor-in-host growth inhibition and cachexia onset during anticancer treatment in in vivo xenograft studies EM Tosca, M Rocchetti, P Magni Oncotarget 12 (14), 1434, 2021 | 8 | 2021 |
| Model‐informed reinforcement learning for enabling precision dosing via adaptive dosing EM Tosca, A De Carlo, D Ronchi, P Magni Clinical Pharmacology & Therapeutics 116 (3), 619-636, 2024 | 7 | 2024 |
| mvLognCorrEst: an R package for sampling from multivariate lognormal distributions and estimating correlations from uncomplete correlation matrix A De Carlo, EM Tosca, N Melillo, P Magni Computer Methods and Programs in Biomedicine 235, 107517, 2023 | 7 | 2023 |
| Artificial intelligence and machine learning: just a hype or a new opportunity for pharmacometrics R Bartolucci, S Grandoni, N Melillo, G Nicora, E Sauta, EM Tosca, ... Page Meet 28, 2019 | 7 | 2019 |
| Predicting admet properties from molecule smile: a bottom-up approach using attention-based graph neural networks A De Carlo, D Ronchi, M Piastra, EM Tosca, P Magni Pharmaceutics 16 (6), 776, 2024 | 5 | 2024 |
| Reinforcement learning and PK‐PD models integration to personalize the adaptive dosing protocol of Erdafitinib in patients with metastatic urothelial carcinoma A De Carlo, EM Tosca, M Fantozzi, P Magni Clinical Pharmacology & Therapeutics 115 (4), 825-838, 2024 | 5 | 2024 |
| Go beyond the limits of genetic algorithm in daily covariate selection practice D Ronchi, EM Tosca, R Bartolucci, P Magni Journal of Pharmacokinetics and Pharmacodynamics 51 (2), 109-121, 2024 | 5 | 2024 |
| In silico trial for the assessment of givinostat dose adjustment rules based on the management of key hematological parameters in polycythemia vera patients EM Tosca, A De Carlo, R Bartolucci, F Fiorentini, S Di Tollo, M Caserini, ... CPT: Pharmacometrics & Systems Pharmacology 13 (3), 359-373, 2024 | 4 | 2024 |
| Modeling resistance development to Bevacizumab in xenograft experiments by coupling hypoxia-mediated mechanism and a Dynamic Energy Budget (DEB) based tumor-in-host model E Tosca, M Rocchetti, E Pesenti, P Magni JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 45, S25-S26, 2018 | 4 | 2018 |
